patrick.net

This article is from a year ago (Nov 4, 2021). Not a word about boosters. Authorization of the Moderna booster was still a month away (Dec 9). So why did they say “initial two shots”?

Undoctored says

This article is from a year ago (Nov 4, 2021). Not a word about boosters. Authorization of the Moderna booster was still a month away (Dec 9). So why did they say “initial two shots”?

Ooops. Will update it.

Hey but this is interesting. Is this an annual occurrence? For reference:

https://www.cnbc.com/2021/11/04/covid-vaccine-moderna-mrna-earnings-q3-2021.html

This is not the article originally posted. It does mention boosters. Apparently they had just been authorized for “tens of millions” of (“high risk”) Americans.

Undoctored says

This is not the article originally posted. It does mention boosters. Apparently they had just been authorized for “tens of millions” of (“high risk”) Americans.

I think the government buys a shit ton. Probably wasted money.

Here's the original article:

https://finance.yahoo.com/news/moderna-stock-plunges-cutting-sales-090010607.html

Not sure how third-world countries are set up logisitically to ensure correct administration of the vax. Could all be a gigantic Biden type skim operation.

https://twitter.com/DrRan/status/1641587134942564353?ref_src=patrick.net

I see no problem with spending taxpayer money to execute the people behind the Wuhan fraud.

https://sashalatypova.substack.com/p/moderna-history-part-1-the-co-founders

Moderna History, Part 1: The Co-Founders
They are a diverse, inclusive, and colorful bunch from Harvard and MIT.

https://www.coffeeandcovid.com/p/rescinded-wednesday-october-18-2023

💉 As I sat down to a blank screen this morning I said to myself, self, I could use some good news to start off the post. And boom! There it was. As the reality of the market’s nearly-complete rejection of the mRNA shots sank in, Moderna’s stock price continued dropping yesterday, now down over 60% so far this year. The drug marketer has only one product it claims to have developed itself — the unsafe and ineffective covid shot.

Moderna probably has not yet hit the bottom. My suggestion: Sell!

Patrick says

Moderna probably has not yet hit the bottom. My suggestion: Sell!

I think Moderna is fucked. MRNA isn't viable. It doesn't work.

I know they are still.pushing the technology but it doesn't work.

I bought it for its tech , not for covid but diabeties etc, they need to come up with something hopefully

Noooooooooooo!

https://twitter.com/VigilantFox/status/1724641530348998662

Moderna ADMITS That DNA Contamination Can Lead to Cancer

• Moderna has a patent that acknowledges RNA is preferable to DNA in vaccines due to risks of insertional mutagenesis, which might activate oncogenes or inhibit tumor suppressor genes, Dr.
@RWMaloneMD
explained.

• A new study up for peer review has found billions of residual DNA fragments in COVID-19 mRNA vaccine vials. In other words, the vials are contaminated with DNA. These findings were not disclosed to the public.

• Additionally, Pfizer, in their documentation to regulatory bodies, omitted information about the presence of SV40 sequences in their vaccine.

• As such, the COVID shots, contaminated with DNA fragments, can cause anything associated with DNA damage — birth defects and cancers being the notable ones.

Moderna targets $1.1B in R&D spending cuts, drops 5 programs amid profitability pressures

Moderna has vowed to cut R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more selective and paced approach” to drug development.

The mRNA specialist expects to spend $4.8 billion on R&D this year. That figure is a problem for a company that wants to turn a profit in the foreseeable future. During the COVID-19 vaccine boom, Moderna generated enough cash to defuse concerns about spending. However, with Pfizer sewing up the European COVID-19 vaccine market for now and contracts stopping Moderna’s respiratory syncytial virus (RSV) vaccine from making a mark on the U.S. this year, the biotech is contending with falling sales.

Moderna set out its response ahead of an R&D day on Thursday. The headline change is the reduction in R&D spending, which the biotech wants to get down to $3.6 billion to $3.8 billion in 2027. Moderna aims to generate the savings through portfolio reprioritizations and cost efficiencies.

Cutting the budget will take time, with Moderna forecasting R&D spending of $4.2 billion to $4.5 billion in 2025.

The biotech disclosed a raft of pipeline changes as part of the announcement. Moderna has axed a plan to file for accelerated approval of its standalone flu vaccine mRNA-1010. The biotech was aiming to seek approval this year but has decided to focus on its flu-COVID combination shot.

Moderna plans to file for approval of the combination vaccine this year and use a priority review voucher. The biotech will start a confirmatory trial of mRNA-1010 this year, using cash from its deal with Blackstone Life Sciences.

Moderna also discontinued five programs. A vaccine designed to prevent endemic human coronaviruses, pathogens that Moderna has previously said cause 1 million outpatient visits a year in the U.S., will stop development before entering the clinic.

The other deprioritized candidates made it into human testing. “Emerging clinical data” has derailed the company's plans to advance a pediatric RSV program and triplet oncology candidate mRNA-2752 beyond phase 1. The cancer asset encodes a T cell co-stimulator and two pro-inflammatory cytokines.

A KRAS antigen-specific therapy, mRNA-5671, and heart failure prospect, mRNA-0184, also failed to make the cut.

Meanwhile, Moderna is continuing development of its Merck & Co.-partnered cancer prospect mRNA-4157 but has hit a regulatory obstacle.

“Initial feedback from FDA has not been supportive of accelerated approval based on the current data,” Moderna said. Talks are ongoing but plans to seek approval may be put back until the partners have data from a “substantially enrolled” phase 3 trial in adjuvant melanoma, the company said.

https://www.fiercebiotech.com/biotech/moderna-targets-11b-rd-spending-cut-drops-5-programs-amid-profitability-pressures

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Moderna (MRNA) stock is plunging Thursday after the COVID-19 vaccine maker announced plans to slash research and development (R&D) expenses and instead focus on receiving approvals for the many drugs in its pipeline.

Moderna's plans include a $1.1 billion reduction in R&D expenses by 2027 to a range of $3.6 billion to $3.8 billion. Rather than spending to explore new products, the company will shift its focus to winning approvals for the 10 products in its pipeline.

"Moderna now has five respiratory vaccines with positive Phase 3 results and expects to submit three for approval this year," said Moderna CEO Stéphane Bancel in a statement. "In addition, we have five non-respiratory products in pivotal studies across cancer, rare diseases and latent vaccines with potential for approval by 2027."

Bancel adds that "the size of our late-stage pipeline combined with the challenge of launching products means we must now focus on delivering these 10 products to patients, slow down the pace of new R&D investment, and build our commercial business."

The shift in strategy comes as Moderna has seen a sharp decline in sales of its COVID-19 vaccine, including a 37% year-over-year decrease in its most recent quarter.

In the release, Moderna also said it anticipates fiscal 2025 revenue to be in the range of $2.5 billion to $3.5 billion and sales to grow at a 25% compound annual growth rate from 2026 to 2028, "driven by new product launches."

The midpoint of MRNA's revenue outlook for its upcoming fiscal year, $3 billion, came in well below analysts' expectations. Wall Street is expecting revenue of $3.74 billion in fiscal 2025, according to Yahoo Finance.

Is Moderna stock a buy, sell or hold?
Moderna had a good run up the price charts to start 2024, but the healthcare stock is now down 33% for the year to date. Still, Wall Street remains bullish on the drugmaker.

According to S&P Global Market Intelligence, the consensus analyst target price for MRNA stock is $125.71, representing implied upside of more than 90% to current levels. Additionally, the consensus recommendation is Buy. However, analysts may revise their targets lower following the reaction to its updated R&D plans.

And some analysts are already on the sidelines when it comes to the large-cap stock, including financial services firm William Blair, which has a Market Perform rating (equivalent to a Hold) on MRNA.

"Like other biotechnology companies with development pipelines, Moderna's risks center on commercial, regulatory, and clinical development," said William Blair analyst Myles Minter in an August 16 note.

The analyst adds that key risks specific to Moderna include the "potential for greater-than-anticipated drop-off in the COVID market, possible failure to show equivalent efficacy across various flu strains versus currently available and other emerging flu vaccines, poor tolerability and/or efficacy with repeat mRNA therapeutics dosing, and other potential clinical setbacks including failed or delayed trials.”

https://www.kiplinger.com/investing/stocks/moderna-stock-plunges-as-vaccine-maker-slashes-randd-budget-what-to-know